ezetimibe has been researched along with pitavastatin in 21 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (pitavastatin) | Trials (pitavastatin) | Recent Studies (post-2010) (pitavastatin) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 730 | 192 | 450 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 8 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S | 1 |
| Hirano, T; Mori, Y | 1 |
| Li, JJ; Li, S; Liu, J; Sun, J; Xu, RX; Zhang, Y | 1 |
| Arashi, H; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Ogawa, H; Yamaguchi, J | 1 |
| Arashi, H; Endoh, Y; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Nakao, K; Ogawa, H; Oka, T; Saito, K; Tanaka, H; Tobaru, T; Uchida, T; Yamaguchi, J | 1 |
| Humphries, KH; Mancini, GBJ | 1 |
| Amano, T; Fujiwara, H; Hibi, K; Ishii, H; Kawasaki, M; Kimura, K; Koshida, R; Kozuma, K; Miyamoto, T; Morino, Y; Morita, S; Murohara, T; Otsuji, Y; Ozaki, Y; Sata, M; Sato, K; Sonoda, S | 1 |
| Arashi, H; Endo, Y; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Nakao, K; Ogawa, H; Oka, T; Saito, K; Sekiguchi, H; Tanaka, H; Tobaru, T; Uchida, T; Yamaguchi, J | 1 |
| Arashi, H; Hagiwara, N; Kanbayashi, K; Kawada-Watanabe, E; Ogawa, H; Sekiguchi, H; Yamaguchi, J | 1 |
| Arashi, H; Hagiwara, N; Haruta, S; Ishii, Y; Kawada-Watanabe, E; Koyanagi, R; Mori, F; Murasaki, S; Ogawa, H; Sekiguchi, H; Suzuki, K; Yamaguchi, J; Yamauchi, T | 1 |
| Arashi, H; Hagiwara, N; Kawada-Watanabe, E; Ogawa, H; Sekiguchi, H; Yamaguchi, J | 1 |
| Christou, EA; Christou, GA; Christou, KA; Christou, MA; Kiortsis, DN; Mprikos, SG; Nikas, DN | 1 |
| Arashi, H; Hagiwara, N; Nakazawa, M; Ogawa, H; Yamaguchi, J | 1 |
| Lei, LC; Li, GP; Peng, JJ; Ren, LH; Wang, ZY; Ye, HM; Zhao, B; Zhao, S | 1 |
| Arashi, H; Hagiwara, N; Kawada-Watanabe, E; Ogawa, H; Otsuki, H; Yamaguchi, J | 1 |
| Chao, TH; Chen, CP; Chou, MT; Hsieh, CH; Huang, CY; Jong, GP; Lee, IT; Lu, CH; McGirr, A; Sheu, WH | 1 |
| Ahn, JC; Cha, DH; Cho, EJ; Cho, JM; Choi, CU; Choi, SY; Gwon, HC; Han, KH; Han, KR; Hong, SJ; Hong, YJ; Jeong, HS; Jeong, YH; Jo, SH; Kang, HJ; Kim, BK; Kim, SH; Kim, WS; Lee, SY; Park, TH; Woo, SI | 1 |
| Ako, J; Suganami, H; Tajima, S; Tanigawa, R; Tsujita, K; Yokote, K | 1 |
1 review(s) available for ezetimibe and pitavastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 trial(s) available for ezetimibe and pitavastatin
| Article | Year |
|---|---|
Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Arginine; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Deoxyguanosine; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acid-Binding Proteins; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Middle Aged; Proteinuria; Quinolines; Severity of Illness Index; Treatment Outcome; Triglycerides | 2010 |
Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
Topics: Acute Coronary Syndrome; Aged; Cholesterol, LDL; Coronary Angiography; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Japan; Male; Middle Aged; Prospective Studies; Quinolines | 2017 |
Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Non-ST Elevated Myocardial Infarction; Prospective Studies; Quinolines; ST Elevation Myocardial Infarction; Treatment Outcome | 2017 |
Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Quinolines; Ultrasonography, Interventional | 2018 |
Predictive Value of Baseline High-Sensitivity C-Reactive Protein Level and Renal Function for Patients With Acute Coronary Syndrome Undergoing Aggressive Lipid-Lowering Therapy: A Subanalysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Prospective Studies; Quinolines; Renal Insufficiency; Single-Blind Method; Time Factors | 2018 |
Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Arachidonic Acid; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids, Unsaturated; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Prognosis; Quinolines; Risk Assessment; Stroke | 2019 |
Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; C-Reactive Protein; Dyslipidemias; Ezetimibe; Female; Humans; Male; Middle Aged; Quinolines; Single-Blind Method | 2020 |
Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Cholesterol, HDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Quinolines; Treatment Outcome | 2020 |
Effect of Ezetimibe + Pitavastatin on Cardiovascular Outcomes in Patients with ST-Segment Elevation Myocardial Infarction (from the HIJ-PROPER Study).
Topics: Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Denmark; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prospective Studies; Quinolines; Single-Blind Method; ST Elevation Myocardial Infarction; Survival Rate; Treatment Outcome | 2020 |
Effect of 1PC111, a Fixed-dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase III Study.
Topics: Aged; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hypercholesterolemia | 2022 |
A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hyp
Topics: Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Treatment Outcome | 2022 |
Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2023 |
8 other study(ies) available for ezetimibe and pitavastatin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol.
Topics: Animals; Anticholesteremic Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Azetidines; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Creatinine; Deoxyguanosine; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Kidney; Kidney Diseases; Kidney Function Tests; Male; Nephrectomy; Proteinuria; Quinolines; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA; Triglycerides | 2012 |
Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats.
Topics: Animals; Azetidines; Drug Combinations; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Proprotein Convertase 9; Quinolines; Rats; Rats, Sprague-Dawley; Serine Endopeptidases | 2014 |
Reduction of LDL-C-related residual cardiovascular risk with ezetimibe: are mechanistic considerations warranted in practice?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Prospective Studies; Quinolines; Risk Factors | 2017 |
Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Predictive Value of Tests; Quinolines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sitosterols; Time Factors; Treatment Outcome | 2018 |
High Tolerability of Pitavastatin Therapy: A Case Report of Comparison with other Statins.
Topics: Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quinolines; Triglycerides | 2020 |
Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarction Patients with Primary Percutaneous Coronary Intervention.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Combined Modality Therapy; Critical Care; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Percutaneous Coronary Intervention; Quinolines; Risk Factors; ST Elevation Myocardial Infarction; Treatment Outcome | 2021 |